Stents: Abbott's Xience Xpedition wins CE Mark

Mon, 08/20/2012 - 8:17am
Mass Device

Abbott's Xience Xpedition coronary stent wins CE Mark approval in the European Union.


Abbott (NYSE:ABT) said its Xience Xpedition coronary stent won CE Mark approval in Europe, with an immediate launch slated for all countries that recognize the mark.


The Chicago-area medical device company said the Xience Xpedition is approved to treat patients with diabetes and requires only 3 months of dual-antiplatelet drug therapy, which Abbott touted as "the shortest duration required for any major drug eluting stent offered in Europe," according to a press release.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.